DEB
Aug 08, 2022
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epidermolysis Bullosa Treatment Market?
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history and low healing rates. Despite current management therapies, the disease has the potential to become severe and devastating for many patients over time. Dystrophic epidermolysis bullosa is classified into six types: dominant dyst...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
